Darovasertib data are promised for the last week of March.
ApexOnco Front Page
Recent articles
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
A rare success for Cabometyx sees a survival benefit, but the control regimen raises questions.
The anti-Siglec-10 MAb ONC-841 features among the latest crop of first-in-human trial initiations.
Randomised data will be needed to answer lingering questions about DKN-01.
Both BCMA-targeting Car-T therapies will face US advisory committee scrutiny after all.
New listings reveal expanded phase 3 programmes for J&J’s Talvey and Amgen’s tarlatamab.
Opdivo plus Yervoy scores a remarkable survival benefit in Checkmate-8HW, whose control arm presents some comparability difficulties.